| 20.36 0.85 (4.36%) | 04-26 15:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 24.61 | 1-year : | 26.47 |
| Resists | First : | 21.07 | Second : | 22.67 |
| Pivot price | 19.91  |
|||
| Supports | First : | 18.5 | Second : | 15.39 |
| MAs | MA(5) : | 19.89 |
MA(20) : | 20.33 |
| MA(100) : | 21.26 |
MA(250) : | 19.06 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 45.5 |
D(3) : | 40.5 |
| RSI | RSI(14): 51.1 |
|||
| 52-week | High : | 26.7 | Low : | 9.26 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CSTL ] has closed below upper band by 31.9%. Bollinger Bands are 28.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 19.72 - 19.83 | 19.83 - 19.92 |
| Low: | 18.5 - 18.64 | 18.64 - 18.74 |
| Close: | 19.31 - 19.51 | 19.51 - 19.69 |
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Mon, 22 Apr 2024
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Movies UK
Sun, 21 Apr 2024
Castle Biosciences, Inc. (NASDAQ:CSTL) Shares Purchased by Knights of Columbus Asset Advisors LLC - MarketBeat
Thu, 11 Apr 2024
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024 - Business Wire
Wed, 10 Apr 2024
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations - Business Wire
Tue, 02 Apr 2024
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference - Business Wire
Fri, 01 Mar 2024
Castle Biosciences, Inc. (NASDAQ:CSTL): Are Analysts Optimistic? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 28 (M) |
| Shares Float | 27 (M) |
| Held by Insiders | 4.2 (%) |
| Held by Institutions | 89.7 (%) |
| Shares Short | 1,430 (K) |
| Shares Short P.Month | 1,210 (K) |
| EPS | -2.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.27 |
| Profit Margin | -26.2 % |
| Operating Margin | -8.6 % |
| Return on Assets (ttm) | -9.5 % |
| Return on Equity (ttm) | -14.6 % |
| Qtrly Rev. Growth | 72.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 7.96 |
| EBITDA (p.s.) | -2.02 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | 1 (M) |
| PE Ratio | -9.57 |
| PEG Ratio | 0 |
| Price to Book value | 1.43 |
| Price to Sales | 2.56 |
| Price to Cash Flow | -100.27 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|